BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Compendia Bioscience and Althea Diagnostics Develop Breast Cancer Segregation Panel(TM) Assay as a Platform for Companion Diagnostic Development


12/9/2010 7:27:05 AM

ANN ARBOR, Mich., Dec. 8, 2010 /PRNewswire-USNewswire/ -- Compendia Bioscience today announced a new strategic partnership with Althea Diagnostics and the immediate availability of the partnership's first joint product and service offerings the Breast Cancer Segregation Panel Assay and Analysis Service.

(Logo: http://photos.prnewswire.com/prnh/20070213/NYTU093LOGO)

The Breast Cancer Segregation Panel measures 96 genes that represent key molecular variability of breast cancer and have been derived from a proprietary meta-analysis of cancer genomic profiles from more than 5,000 clinical samples. The assay has been optimized by Althea Diagnostics to measure the genes using quantitative RT-PCR from formalin-fixed tissue (FFPE) samples to enable rapid translation to real-world clinical settings.

Compendia Bioscience will analyze the data generated by the assay and will perform correlation studies to end-points of interest such as drug response. This will allow for development of multiple drug-specific companion diagnostics from a standardized platform.

"This addresses a critical concern," said Scott Tomlins, M.D., Ph.D., a scientific advisor from the University of Michigan. "Clinicians could soon become overwhelmed by the number of molecular diagnostics entering the market, each requiring precious tissue samples. A standard assay that could be used to address a number of different clinical questions will be highly valuable to the field. We are hopeful that future studies will prove the utility of Compendia's approach."

The partnership leverages the unique expertise of each company. Compendia Bioscience is a recognized leader in the cancer genomics data collection, curation and analysis. Althea Diagnostics has a long pedigree in gene quantification from FFPE samples and is a leading provider of diagnostic development services for pharmaceutical companies.

"We are excited to announce this new partnership with Althea Diagnostics," said Dan Rhodes, Ph.D., Compendia's co-founder and CEO. "We have been looking for the right partner to develop our breast segregation panel technology and have been pleased by the rapid progress from our joint development team with Althea."

Althea Diagnostics CEO, François Ferre, Ph.D., said, "Compendia has such a strong scientific presence within cancer drug discovery and development companies that it was an easy choice to partner with them. They are thought-leaders in the application of cancer genomics and we are thrilled by this new and productive partnership."

The companies have also announced that they plan to develop similar assays for other cancer disease types. The companies have begun development of a Colon Segregation Panel assay, which will be available in 2011.

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to applying the global collection of cancer genomic data to impact patient treatment by enabling the discovery and development and better cancer diagnostics and treatments. www.compendiabio.com

SOURCE Compendia Bioscience, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES